Novax acquires majority of Ulrick & Short Novax has acquired a majority stake in UK ingredient supplier Ulrick & Short as part of its drive into the food sector.
Announcing the transaction, Novax – the investment arm of Swedish group Axel Johnson – said Ulrick & Short will continue to operate as a standalone business. The company’s founders Adrian Short and Andrew Ulrick will remain minority shareholders and the existing management team will remain in place under the leadership of Short as CEO.
“From the first meeting with the Novax team it was clear we had found an organisation and group of people that shared our values and beliefs of how a business should be nurtured and developed,” Short commented.
Press release content from PR Newswire. The AP news staff was not involved in its creation.
The Stepping Stones Group acquires EBS Healthcare
March 15, 2021 GMT
SSG (PRNewsfoto/The Stepping Stones Group)
BOSTON, March 15, 2021 /PRNewswire/ The Stepping Stones Group (Stepping Stones) is delighted to announce the acquisition of EBS Healthcare (EBS), a Pennsylvania-based therapeutic and behavioral company. The combination of Stepping Stones and EBS creates a premier, national provider of therapeutic, behavioral, autism, nursing and educational services to children in school, home and community settings. As a mission driven organization, the combined company will transform the lives of children, families and communities in over 900 school districts across 42 states.
Press release content from Business Wire. The AP news staff was not involved in its creation.
H.I.G. Europe Exits Infinigate to Bridgepoint Following Successful European Expansion
March 15, 2021 GMT
HAMBURG, Germany (BUSINESS WIRE) Mar 15, 2021
H.I.G. Capital (“H.I.G.“), a leading global alternative investment firm with over €35 billion of equity capital under management, is pleased to announce that an affiliate has signed a definitive agreement to sell Infinigate (the “Company”) to Bridgepoint, an international alternative asset fund management group. H.I.G. acquired a majority stake in the Company in 2017. The transaction is subject to clearance by the relevant antitrust authorities.
Roche has inked a $1.8 billion, all-cash deal for GenMark Diagnostics, to acquire its molecular tests designed to screen patient samples for multiple infections simultaneously.